Overview of rapid microbiological methods evaluated, validated and implemented for microbiological quality control

19 April 2011  •  Author(s): Oliver Gordon, Jennifer C. Gray, Hans-Joachim Anders, Alexandra Staerk & Oliver Schlaefli, Novartis Pharma Stein AG and Gunther Neuhaus, University of Freiburg

The risk for patients through spoiled or otherwise adulterated pharmaceuticals has been acknowledged for many centuries and led to the establishment of Good Manufacturing Practice (GMP) and pharmacopoeial guidelines. Besides chemical purity, pharmaceuticals also have to meet microbiological standards, the latter primarily depending on the administration route. Drug products which are injected directly into blood vessels or tissues or that are applied directly into eyes and ears represent a greater infection risk than products which are administered orally or onto intact healthy skin. While parenteral drug products are required to be free from any viable microorganism (USP , Ph. Eur. 2.6.1), oral and topical products are not required to be sterile, but are subject to strict guidelines limiting the number and types of acceptable microorganisms (USP and , Ph. Eur. 2.6.12 and 2.6.13).

The rest of this content is restricted to logged-in subscribers. Login or register (it's free!) to view the full content.

Comments are closed.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...